1,2,3-三溴-5-硝基苯 | 3460-20-6

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类硝化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,2,3-三溴-5-硝基苯
• 英文名称: 3,4,5-Tribromnitrobenzen
• 英文别名: 1,2,3-tribromo-5-nitrobenzene；3,4,5-tribromonitrobenzene；3,4,5-Tribromnitrobenzol；1,2,3-Tribrom-5-nitro-benzol
• CAS: 3460-20-6
• 化学式: C₆H₂Br₃NO₂
• mdl: MFCD02657489
• 分子量: 359.799
• InChiKey: AKLYERMMCABILW-UHFFFAOYSA-N

物化性质

• 熔点：
  112°C
• 沸点：
  344.48°C (estimate)
• 密度：
  2.4010 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2904909090

反应信息

• 作为反应物：
  描述：

  1,2,3-三溴-5-硝基苯 在 乙醇 、 氨 作用下， 生成 2,6-二溴-4-硝基苯胺
  参考文献：
  名称：

  Koerner, Gazzetta Chimica Italiana, 1874, vol. 4, p. 341

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-二溴硝基苯 在 盐酸 、 乙醇 、 氨 、 溴 作用下， 生成 1,2,3-三溴-5-硝基苯
  参考文献：
  名称：

  Koerner, Gazzetta Chimica Italiana, 1874, vol. 4, p. 341

  摘要：

  DOI：

文献信息

• 1-Aryl-3,3-dialkyltriazenes: A Convenient Synthesis from Dry Arenediazonium o-Benzenedisulfonimides - A High Yield Break Down to the Starting Dry Salts and Efficient Conversions to Aryl Iodides, Bromides and Chlorides
  作者：Margherita Barbero、Iacopo Degani、Nicola Diulgheroff、Stefano Dughera、Rita Fochi

  DOI：10.1055/s-2001-18072

  日期：——

  Synthesis 2001, No. 14, 26 1

  综合 2001, No. 14, 26 1
• Substituted bis-(4-aminophenyl)-sulfones
  申请人：Dr. Karl Thomae GmbH

  公开号：US04829058A1

  公开（公告）日：1989-05-09

  Disclosed are substituted bis(4-aminophenyl)-sulfones of general formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or cycloalkyl; group, R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 is nitrile, C.sub.1 -C.sub.3 alkylaminocarbonyl, di C.sub.1 -C.sub.3 alkylaminocarbonyl, C.sub.3 -C.sub.7 N-cycloalkyl-C.sub.1 -C.sub.3 alkylaminocarbonyl C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C.sub.1 -C.sub.3 alkylaminono, diC.sub.1 -C.sub.3 alkylaminosulfonyl, hydroxy C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylcarbonyl, amino C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy C.sub.1 -C.sub.3 alkyl group or, when R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 can be hydroxy, hydroxycarbonyl C.sub.1 -C.sub.3 alkoxy or di C.sub.1 -C.sub.3 aminocarbonylalkoxy; or, when R.sub.1 is C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 cycloalkyl and R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C.sub.1 -C.sub.3 alkyl, carboxy or C.sub.1 -C.sub.3 alkoxycarbonyl; and R.sub.4 is hydrogen or, when R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is halogen or hydroxy, R.sub.4 can also be halogen, hydroxy or C.sub.1 -C.sub.3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductase inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.

  揭示了通式##STR1##中的取代双(4-氨基苯基)-砜，其中R.sub.1是氢、烷基或环烷基；基团，R.sub.2是氢或C.sub.1 -C.sub.3烷基，R.sub.3是腈基、C.sub.1 -C.sub.3烷基氨基甲酰基、二C.sub.1 -C.sub.3烷基氨基甲酰基、C.sub.3 -C.sub.7-N-环烷基-C.sub.1 -C.sub.3烷基氨基甲酰基、C.sub.1 -C.sub.3烷基氨基、C.sub.1 -C.sub.3，二烷基氨基甲酰基烷氧基、烷基氨基磺酰基、二C.sub.1 -C.sub.3烷基氨基磺酰基、羟基C.sub.1 -C.sub.3烷基、C.sub.1 -C.sub.3烷基羰基、氨基C.sub.1 -C.sub.3烷基或C.sub.1 -C.sub.3烷氧基烷基基团或者，当R.sub.1和R.sub.2分别为氢时，R.sub.3可以是羟基、羟基羰基C.sub.1 -C.sub.3烷氧基或二C.sub.1 -C.sub.3氨基甲酰氧基；或者，当R.sub.1为C.sub.1 -C.sub.3烷基或C.sub.1 -C.sub.3环烷基且R.sub.2为氢或C.sub.1 -C.sub.3烷基时，R.sub.3还可以是卤素、三氟甲基、硝基、氨基、氨基磺酰基、氨基甲酰基、C.sub.1 -C.sub.3烷基、羧基或C.sub.1 -C.sub.3烷氧羰基；以及R.sub.4是氢或者，当R.sub.1和R.sub.2分别为氢且R.sub.3为卤素或羟基时，R.sub.4还可以是卤素、羟基或C.sub.1 -C.sub.3烷氧基；或其无毒的、药学上可接受的盐。还揭示了包含这种化合物的药物组合物，单独使用或与二氢叶酸还原酶抑制剂结合。这些化合物和组合物对细菌、分枝杆菌和疟原虫的抑制作用很有用。
• Anti-bacterial compositions comprising a substituted
  申请人：Dr. Karl Thomae GmbH

  公开号：US05084449A1

  公开（公告）日：1992-01-28

  Disclosed are substituted bis(4-aminophenyl-sulfonees of general formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or cycloalkyl; group, R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 is nitrile, C.sub.1 -C.sub.3 alkylaminocarbonyl, di C.sub.1 -C.sub.3 alkylaminocarbonyl, C.sub.3 -C.sub.7 N-cycloalkyl-C.sub.1 -C.sub.3 alkylaminocarbonyl C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3, di alkylaminocarbonyl alkoxy, alkylaminosulfonyl, di C.sub.1 -C.sub.3 alkylaminono, diC.sub.1 -C.sub.3 alkylaminosulfonyl, hydroxy C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylcarbonyl, amino C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy C.sub.1 -C.sub.3 alkyl group or, when R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 can be hydroxy, hydroxycarbonyl C.sub.1 -C.sub.3 alkoxy or di C.sub.1 -C.sub.3 aminocarbonylalkoxy; or, when R.sub.1 is C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 cycloalkyl and R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl, R.sub.3 can also be halogen, trifluoromethyl, nitro, amino, aminosulfonyl, aminocarbonyl, C.sub.1 -C.sub.3 alkylo, carboxy or C.sub.1 -C.sub.3 akoxycarbonyl; and R.sub.4 is hydrogen or, when R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is halogen or hydroxy, R.sub.4 can also be halogen, hydroxy or C.sub.1 -C.sub.3 alkoxy; or a nontoxic, pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising such compounds alone and in combination with dihydrofolic acid-reductage inhibitors. The compounds and compositions are useful for their inhibiting effect on bacteria, mycobacteria and plasmodia.

  揭示了一种通用式为##STR1##的取代的双(4-氨基苯基-砜)化合物，其中R.sub.1是氢、烷基或环烷基；基团，R.sub.2是氢或C.sub.1-C.sub.3烷基，R.sub.3是腈、C.sub.1-C.sub.3烷基氨基羰基、二C.sub.1-C.sub.3烷基氨基羰基、C.sub.3-C.sub.7 N-环烷基-C.sub.1-C.sub.3烷基氨基羰基、C.sub.1-C.sub.3烷基氨基、C.sub.1-C.sub.3, 二烷基氨基羰基氧基、烷基氨基磺酰基、二C.sub.1-C.sub.3烷基氨基、二C.sub.1-C.sub.3烷基氨基磺酰基、羟基C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷基羰基、氨基C.sub.1-C.sub.3烷基或C.sub.1-C.sub.3烷氧基烷基或，当R.sub.1和R.sub.2分别为氢时，R.sub.3可以是羟基、羟基羰基C.sub.1-C.sub.3烷氧基或二C.sub.1-C.sub.3氨基羰基氧基；或者，当R.sub.1为C.sub.1-C.sub.3烷基或C.sub.1-C.sub.3环烷基且R.sub.2为氢或C.sub.1-C.sub.3烷基时，R.sub.3也可以是卤素、三氟甲基、硝基、氨基磺酰基、氨基羰基、C.sub.1-C.sub.3烷氧、羧基或C.sub.1-C.sub.3氧羰基；而R.sub.4是氢或，当R.sub.1和R.sub.2分别为氢且R.sub.3为卤素或羟基时，R.sub.4也可以是卤素、羟基或C.sub.1-C.sub.3烷氧；或其无毒的、药学上可接受的盐。还揭示了包含这种化合物的药物组合物，单独使用或与二氢叶酸还原酶抑制剂结合。这些化合物和组合物对细菌、分枝杆菌和疟原虫的抑制作用具有用处。
• A Strategy towards the Multigram Synthesis of Uncommon Hexaarylbenzenes
  作者：Dominik Lungerich、David Reger、Helen Hölzel、René Riedel、Max M. J. C. Martin、Frank Hampel、Norbert Jux

  DOI：10.1002/anie.201600841

  日期：2016.4.25

  (FpNA)—provides substituted hexaarylbenzenes (HABs) with uncommon symmetries that bear up to five different substituents, fully avoiding regioisomeric product distributions during the reactions. 4‐Nitroaniline is functionalized by a cascade of electrophilic halogenations, Sandmeyer brominations, and Suzuki cross‐coupling reactions, leading to 26 substitution geometries, of which 18 structures are not available

  一种新颖的理性合成途径-“对位的功能化”“硝基苯胺”（FpNA）-提供具有不常见对称性的取代六芳基苯（HAB），最多可带有五个不同的取代基，从而完全避免了反应过程中区域异构产物的分布。4-硝基苯胺通过一系列亲电子卤化，Sandmeyer溴化和Suzuki交叉偶联反应而功能化，从而导致26种取代几何结构，其中18种结构无法通过当前已建立的技术获得。此外，我们证明了该方法适用于以克为单位的此类系统的批量生产。关于光电性能，我们证明了高度官能化的HAB如何表现出强大的发光性能，从而使这些分子对有机电子设备非常有吸引力。
• Computational and Experimental Evidence of Emergent Equilibrium Isotope Effects in Anion Receptor Complexes
  作者：Blakely W. Tresca、Alexander C. Brueckner、Michael M. Haley、Paul H.-Y. Cheong、Darren W. Johnson

  DOI：10.1021/jacs.7b00612

  日期：2017.3.22

  The measurement of a deuterium equilibrium isotope effect (EIE) for the aryl CH···Cl– interaction of anion receptor 1H/1D is reported. Computations corroborate the results of solution measurements for a small, normal EIE in the full complex (KaH/KaD = 1.019 ± 0.010). Interestingly, isotope effects involving fragments of the anion receptor (urea, aryl ring, etc.) are predicted to produce an inverse

  报道了阴离子受体 1H/1D 的芳基 CH…Cl– 相互作用的氘平衡同位素效应 (EIE) 的测量。计算证实了完整复合体中小型正常 EIE 的解决方案测量结果 (KaH/KaD = 1.019 ± 0.010)。有趣的是，涉及阴离子受体片段（尿素、芳环等）的同位素效应预计会产生相反的效应。这表明阴离子受体复合物的异常和微妙的结构组织效应将组合相互作用的性质改变为正常的同位素效应。EIE 值的反转表明阴离子受体的整体结构可以显着影响这些复合物中键合的性质。

表征谱图